CACecilia Adelöw

Cecilia Adelöw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecilia Adelöw has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Anders Ahlbom

    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Tomas Andersson

    Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    1 shared publication
  • Torbjörn Tomson

    Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden

    1 shared publication

Latest Publications

  • Prior hospitalization for stroke, diabetes, myocardial infarction, and subsequent risk of unprovoked seizures

    by Cecilia Adelöw, Tomas Andersson, Anders Ahlbom, Torbjörn Tomson

    Summary: Purpose:  To study diabetes, acute myocardial infarction, and stroke as risk factors for unprovoked seizures in a population‐based cohort with incident cases of epilepsy.Methods:  In this nested case–control study, the cases were 933 patients with newly diagnosed unprovoked seizures from the Stockholm Incidence Registry of Epilepsy. Controls, in total 6,039—matched for gender, year of diagnosis, and catchment area—were randomly selected from the register of the Stockholm County population. A history of diabetes, myocardial infarction, and stroke preceding the date of onset of seizure was determined by search of the Swedish Hospital Discharge Registry. Odds ratios (ORs) were calculated to assess the risk of developing unprovoked seizures after hospital admission for any of these diagnoses.Results:  The age‐adjusted OR (95% confidence interval, 95% CI) for unprovoked seizures after a discharge diagnosis of diabetes was 1.9 (95% CI 1.4–2.8) and after acute myocardial infarction 1.7 (95% CI 1.0–2.9). The OR was 9.4 (95% CI 6.7–13.1) after cerebral infarction, 7.2 (95% CI 3.9–13.6) after intracerebral hemorrhage, 7.2 (95% CI 2.9–18.1) after subarachnoid hemorrhage, and 3.2 (95% CI 1.9–5.5) after transient ischemic attack. The population attributable risk percent (PAR%) was 7 years after a diagnosis of cerebral infarction.


  • Epilepsy as a risk factor for cancer

    by C Adelow

    Epilepsy and long term use of antiepileptic drugs have been suggested to be associated with an increased risk of cancer. The authors therefore set out to analyse previous diagnosis of epilepsy as a risk factor for certain cancer forms in a case control study. Incident cases of leukaemia, lymphoma, myeloma, and pancreatic cancer were identified from the Swedish Cancer Registry 1987-99, a total of 52 861 cases. Controls (n = 137 485) were randomly selected from the Swedish Population Registry stratified on age, sex, and year of cancer diagnosis. Cases and controls were linked to the Swedish Hospital Discharge Registry for 1969-99 to identify individuals with first time hospital discharge for epilepsy. While an epilepsy diagnosis the same year as a cancer diagnosis carried an increased risk of non-Hodgkin's lymphoma (OR = 2.89, 95% CI 1.89 to 4.41), Hodgkin's disease (OR = 4.77, 95% CI 1.77 to 13.30), leukaemia (OR = 2.55, 95% CI 1.50 to 4.32), acute myeloid leukaemia (OR = 3.65, 95% CI 1.68 to 7.93), and pancreatic cancer (OR = 2.05, 95% CI 1.22 to 3.45), the authors found no support for an association between discharge with a diagnosis of epilepsy two years or more before the diagnosis of cancer and an increased risk of any of the types of cancer included in this analysis. The lack of association was also evident for individuals with an epilepsy diagnosis preceding malignancy/reference year by >10 years. Clinical examinations prompted by seizure onset probably mainly explain the observed association between epilepsy diagnoses the year before a cancer diagnosis. However, these results lend no support to the suggestion that epilepsy, and presumably long term exposure to antiepileptic drugs, is associated with an increased risk of the types of cancer included in the present study.